Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Collinge

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Regulatory Toxicology and Pharmacology : RTP|February 26, 2014
The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: study design, data analysis, interpretationHervé Lebrec, Brigitte Molinier, Darrell Boverhof, et al.
The Journal of Clinical Investigation|November 2, 2013
Transmembrane protein ESDN promotes endothelial VEGF signaling and regulates angiogenesisLei Nie, Xiaojia Guo, Leila Esmailzadeh, et al.
Regulatory Toxicology and Pharmacology : RTP|April 20, 2024
Challenges and gaps in immunosafety evaluation of therapeutics: An IQ DruSafe surveyMark Collinge, Haley Neff-LaFord, Surekha Akella, et al.
Toxicologic Pathology|March 8, 2014
Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®)Anne M Ryan, Sharon A Sokolowski, Chee-Keng Ng, et al.
The Journal of Toxicological Sciences|March 1, 2021
Microphysiological systems in early stage drug development: Perspectives on current applications and future impactAnna K Kopec, Ryuji Yokokawa, Nasir Khan, et al.
Clinical Immunology (Orlando, Fla.)|March 9, 2018
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteersKent J Weinhold, Jack F Bukowski, Todd V Brennan, et al.
Advanced Drug Delivery Reviews|February 18, 2014
Challenges for inhaled drug discovery and development: Induced alveolar macrophage responsesBen Forbes, Raegan O'Lone, Philippa Pribul Allen, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 4, 2023
A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6<sup>+</sup> T Cells, and Ameliorates Interleukin-23-Induced Skin InflammationWei Li, Kimberly K Crouse, Jennifer Alley, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Regulatory Toxicology and Pharmacology : RTP|February 26, 2014
The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: study design, data analysis, interpretationHervé Lebrec, Brigitte Molinier, Darrell Boverhof, et al.
The Journal of Clinical Investigation|November 2, 2013
Transmembrane protein ESDN promotes endothelial VEGF signaling and regulates angiogenesisLei Nie, Xiaojia Guo, Leila Esmailzadeh, et al.
Regulatory Toxicology and Pharmacology : RTP|April 20, 2024
Challenges and gaps in immunosafety evaluation of therapeutics: An IQ DruSafe surveyMark Collinge, Haley Neff-LaFord, Surekha Akella, et al.
Toxicologic Pathology|March 8, 2014
Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®)Anne M Ryan, Sharon A Sokolowski, Chee-Keng Ng, et al.
The Journal of Toxicological Sciences|March 1, 2021
Microphysiological systems in early stage drug development: Perspectives on current applications and future impactAnna K Kopec, Ryuji Yokokawa, Nasir Khan, et al.
Clinical Immunology (Orlando, Fla.)|March 9, 2018
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteersKent J Weinhold, Jack F Bukowski, Todd V Brennan, et al.
Advanced Drug Delivery Reviews|February 18, 2014
Challenges for inhaled drug discovery and development: Induced alveolar macrophage responsesBen Forbes, Raegan O'Lone, Philippa Pribul Allen, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 4, 2023
A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6<sup>+</sup> T Cells, and Ameliorates Interleukin-23-Induced Skin InflammationWei Li, Kimberly K Crouse, Jennifer Alley, et al.
Pageof 3